Efficacy and clinical application of momelotinib

Momelotinib is a targeted drug that has received widespread attention in recent years. It is mainly used to treat hematological malignant diseases such as myelofibrosis (MF). The disease is often accompanied by symptoms of anemia, splenomegaly and general weakness, seriously affecting the patient's quality of life. As an oral JAK1/JAK2 inhibitor, molotinib also has a unique effect on ACVR1 and can inhibit disease progression while improving anemia. This has significant advantages over previous similar drugs. Its mechanism not only controls abnormal bone marrow proliferation by inhibiting the JAK-STAT signaling pathway, but also helps increase red blood cell levels by affecting iron metabolism-related pathways, thereby reducing blood transfusion dependence.

From a clinical application perspective, molotinib is mainly used for patients with intermediate and high-risk myelofibrosis, especially those with obvious anemia symptoms. In past treatment strategies, although other JAK inhibitors can relieve splenomegaly and improve some symptoms, they are often insufficient in the treatment of anemia and may even aggravate anemia due to bone marrow suppression. Molotinib has shown the potential to improve hematological parameters in clinical applications, which has gradually gained a place in international guideline recommendations. Overseas data show that the drug can not only significantly reduce the size of the spleen and improve patients' night sweats, bone pain and fatigue, but also has long-term value in improving quality of life.

In addition, molotinib is administered orally once daily to facilitate long-term disease management for patients. During treatment, doctors will decide whether to use molotinib based on the patient's disease course, degree of anemia, and tolerance to previous drugs. As more research data accumulates, the application scenarios of this drug in myelofibrosis may be further expanded. For Chinese patients, although the current listing is still progressing, its widespread application overseas has brought new clinical options in the future.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib